The six-month results from the single-arm TRILUMINATE Feasibility trial confirm Abbott Laboratories Inc.’s TriClip, a tricuspid version of Abbott’s MitraClip mitral valve repair device, improves both clinical endpoints and quality of life for patients with tricuspid regurgitation.
Lead investigator Georg Nickenig of University Hospital in Bonn, Germany, presented the data at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco on 28 September.